1. Home
  2. SCLX vs CBAN Comparison

SCLX vs CBAN Comparison

Compare SCLX & CBAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • CBAN
  • Stock Information
  • Founded
  • SCLX 2011
  • CBAN 1975
  • Country
  • SCLX United States
  • CBAN United States
  • Employees
  • SCLX N/A
  • CBAN N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • CBAN Major Banks
  • Sector
  • SCLX Health Care
  • CBAN Finance
  • Exchange
  • SCLX Nasdaq
  • CBAN Nasdaq
  • Market Cap
  • SCLX 143.6M
  • CBAN 229.6M
  • IPO Year
  • SCLX N/A
  • CBAN 1998
  • Fundamental
  • Price
  • SCLX $1.04
  • CBAN $14.73
  • Analyst Decision
  • SCLX Strong Buy
  • CBAN
  • Analyst Count
  • SCLX 3
  • CBAN 0
  • Target Price
  • SCLX $8.00
  • CBAN N/A
  • AVG Volume (30 Days)
  • SCLX 184.3K
  • CBAN 38.4K
  • Earning Date
  • SCLX 08-13-2024
  • CBAN 10-23-2024
  • Dividend Yield
  • SCLX N/A
  • CBAN 3.06%
  • EPS Growth
  • SCLX N/A
  • CBAN 5.35
  • EPS
  • SCLX N/A
  • CBAN 1.26
  • Revenue
  • SCLX $50,833,000.00
  • CBAN $109,415,000.00
  • Revenue This Year
  • SCLX $89.87
  • CBAN N/A
  • Revenue Next Year
  • SCLX N/A
  • CBAN $6.75
  • P/E Ratio
  • SCLX N/A
  • CBAN $11.65
  • Revenue Growth
  • SCLX 9.41
  • CBAN N/A
  • 52 Week Low
  • SCLX $0.73
  • CBAN $9.36
  • 52 Week High
  • SCLX $2.69
  • CBAN $15.80
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 26.85
  • CBAN 58.86
  • Support Level
  • SCLX $1.04
  • CBAN $14.72
  • Resistance Level
  • SCLX $1.11
  • CBAN $15.38
  • Average True Range (ATR)
  • SCLX 0.08
  • CBAN 0.43
  • MACD
  • SCLX 0.00
  • CBAN -0.00
  • Stochastic Oscillator
  • SCLX 8.20
  • CBAN 44.74

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About CBAN Colony Bankcorp Inc.

Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division, and small business specialty lending divisions. It generates maximum revenue from the Banking Division.

Share on Social Networks: